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discussed within a multidisciplinary board. When adjuvant RT 
is indicated, conformal RT should be used. Patients should be 
followed up as late recurrences may occur 
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Purpose or Objective: PET/CT based radiotherapy planning 
(RTP) has been shown to improve the consistency of target 
volume delineation (TVD) in lung cancer radiotherapy, 
hopefully leading to improved local control. This study 
assesses the impact of a standardized delineation protocol 
and multiple training interventions on PET/CT based TVD in 
NSCLC. 
 
Material and Methods: Over a one year period, nuclear 
medicine physicians (NMP) and radiation oncologists (RO) 
with limited experience in PET/CT based TVD from nine 
different countries participated in a multicenter study. The 
first training intervention included a three-day training 
course, consisting of three contouring assignments which 
formed the basis of a teaching discussion with the aim of 
identifying and correcting misinterpretations of practical 
guidelines, and various lectures on PET/CT based RTP. The 
second training event contained detailed individual feedback 
reports about previous performed contouring assignments and 
a webinar on PET/CT based TVD in NSCLC. Eleven teams 
consisting of a RO and NMP performed joint gross tumor 
volume (GTV) delineation of the primary tumor as per a 
standardized delineation protocol. In-house developed 
software called Big Brother recorded any user-software 
interaction, consequently allowing visual inspection of 
delineation strategies. Six delineation cases were performed 
before, during and after the training program and were 
compared with agreed expert contours (GTVexp) to assess 
delineation performance. 
 
Results: Following the three-day training course overall 
concordance indices for 3 repetitive cases increased from 
0.57±0.11 (SD) to 0.66±0.10. Observer volumes were larger 
after the training and miss of GTVexp was significantly 
reduced from 79.01±52.35 cc (SD) to 42.86±38.08 cc. Results 
are summarized in table 1. After further feedback and the 
webinar overall concordance indices for another 3 repetitive 
cases increased from 0.64±0.10 (SD) to 0.80±0.08. A 
reduction of GTVexp miss from 78.89±44.51 cc (SD) to 
30.87±20.26 cc was observed.  
 
Conclusion: Following a training intervention, PET/CT based 
TVD in NSCLC RTP using a standardized delineation protocol 
led to significant improvement in delineation performance. A 
greater improvement in TVD with the use of multiple training 
events as compared to a single training event was observed. 
 
PO-0684  
Does the dose to heart affect survival in NSCLC patient 
treated with definitive Radiotherapy? 
T. Schytte
1Odense University Hospital, Department of Oncology, 
Odense, Denmark 
1, T.B. Nielsen2, T. Stolberg-Rohr2, C. Brink2, O. 
Hansen1 
2Odense University Hospital, Laboratory of Radiation Physics, 
Odense, Denmark 
 
Purpose or Objective: High radiotherapy dose to the heart 
increase the risk of cardiac morbidity and death in early 
stage breast cancer and lymphoma. Recent reports (1,2) have 
indicated that an association between overall survival and 
dose to heart (e.g. V5 for the heart) are observable after 
radiotherapy of NSCLC patients as well. The objective of this 
study was to evaluate if overall survival was affected by high 
V5 to the heart in NSCLC patients treated with definitive 
radiotherapy (RT).  
1) Bradley et al, Lancet Oncology 2015 Feb;16(2):187-99. 2) 
Belderbos et al, WCLC2015 mini33.03) 
 
Material and Methods: In a single institution, 297 NSCLC 
patients were treated consecutively with definitive RT from 
2001-2007 with at least 60 Gy. Concomitant chemotherapy 
was not part of the standard treatment initially but became a 
treatment option later in the study period (weekly 
docetaxel). RT was delivered as 3D RT without elective nodal 
irradiation. No constraint on dose to the heart was applied 
during treatment planning. The heart was delineated 
retrospectively and heart doses were extracted from the 
treatment planning system (mean heart dose (MHD) and V5). 
Patients were stratified in two groups depending on their 
heart dose being above or below the median value. Survival 
test was performed using Kaplan Meyer and log-rank test. All 
patients were followed to death. 
 
Results: Patient and treatment characteristics are 
summarized in table 1. Median follow-up was 127 months. 
The overall median survival was 19.1 months with 1, 2 and 5 
year survival of 69%, 41%, and 17%, respectively. Median V5 
for the heart was 49%. No association between survival and 
heart dose were observed (p=0.29 see Fig 1). The same was 
true when including smoking, gender, and concomitant 
chemotherapy as strata in the analyses. Median MHD was 14 
Gy. Survival for patients with MHD ≥14 Gy or <14 Gy was 17% 
and 21%, respectively (p=0.83). 
